tirzepatide journey Essential Log | Continues: The Ultimate Companion Tracker for Your Continued Weight Loss Journey Using Medication Support My Tirzepatide Journey ( -

What are your thoughtsdo you think this will lead to stricter regulation or change in pharma practices

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

Weight loss peptides retatrutide explained: how this investigational triple agonist works, what Phase 2 trial data shows, UK regulatory status, side effects, and who may be suitable for peptide-based obesity treatment.

Dive in and learn more today!

Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors two gut hormone pathways involved in appetite regulation and blood sugar control

Study: TripleHormone Receptor Agonist Retatrutide for Obesity (Phase 2 Trial, NEJM) Drug: Retatrutide a triple agonist (GLP-1, GIP, and glucagon receptors) Key Findings: Up to 28.7% mean weight loss at higher doses Marked improvements in insulin sensitivity and cardiometabolic risk factors Weight loss approaching outcomes seen with bariatric surgery, without surgery What makes Retatrutide unique is its triple-hormone mechanism, simultaneously targeting appetite regulation, energy expenditure, and glucose metabolism